Evaluating the potential of 188re-ecd/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment

Tsai Yueh Luo, Ying Hsia Shih, Chiung Yu Chen, I. Chung Tang, Yu Long Wu, Hong Chang Kung, Wuu Jyh Lin, Xi Zhang Lin

研究成果: Article同行評審

9 引文 斯高帕斯(Scopus)


Background/Objectives: Intratumoral injection of a radiopharmaceutical is a potential modality to treat liver tumors. Rhenium-188 (188Re) was used to chelate with ethyl cysteinate dimer (ECD) in lipiodol solution to form 188Re-ECD/lipiodol, which was then evaluated for its therapeutic potential in a rodent hepatoma model. Materials and Methods: Male Sprague-Dawley rats were implanted with N1-S1 hepatoma cells orthotopically and randomly divided into two groups. Group 1 (=29) and group 2 (=10) received 188Re-ECD/lipiodol (30.4 > ±21.8MBq/0.1mL) and 0.1 mL of normal saline by intratumoral injection, respectively. Three rats in group 1 were imaged by micro-single-photon emission computed tomography/computed tomography scan to evaluate the biodistribution pattern. All rats were monitored for change of tumor size and survival rate after 2 months. Results: The in vitro stability test showed that 188Re-ECD was well-retained in the lipiodol phase for 48 hours. The biodistribution image revealed that radioactivity was retained well in hepatomas 24 hours postinjection. Long-term studies demonstrated that rats treated with 188Re-ECD/Lipiodol had smaller tumor volumes and a better survival rate, compared to the control group. At the end of observation, the survival rates in groups 1 and 2 were 62% and 20%, respectively (p<0.05). Conclusions: 188Re-ECD/lipiodol via direct intratumoral injection shows potential for treating hepatoma and warrants further clinical trials.

頁(從 - 到)535-541
期刊Cancer Biotherapy and Radiopharmaceuticals
出版狀態Published - 2009 十月 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

指紋 深入研究「Evaluating the potential of <sup>188</sup>re-ecd/lipiodol as a therapeutic radiopharmaceutical by intratumoral injection for hepatoma treatment」主題。共同形成了獨特的指紋。